IPOs/Nasdaq Capital Market/2026/Retension Pharmaceuticals, Inc.

Retension Pharmaceuticals, Inc. RTSN

Retension Pharmaceuticals, Inc. (RTSN) priced its IPO on Nasdaq Capital Market on October 9, 2026 at $12.00 a share. Clinical-stage biopharmaceutical company developing RTN-001, a next-generation oral PDE-5 inhibitor for treating hypertension and cardiovascular diseases. Based in Falls Church, Virginia.

Registered
Priced
TradingNot yet
Offer price
$12.00
Raised
Not given
Shares offered
3,750,000 shares
Lock-up
180 days
See the prospectus →

The company

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing RTN-001, a next-generation oral PDE-5 inhibitor for treating hypertension and cardiovascular diseases. It is based in Falls Church, Virginia. It sold 3,750,000 shares at $12.00 per share.

The company will receive $38.9 million in net proceeds to complete the Phase 2b clinical trial, prepare for, support and advance the planned Phase 3 clinical trial of RTN-001 in uHTN, and for general corporate purposes and other operating expenses. The company sold 3,750,000 shares and existing shareholders sold 0 shares.

Where the money goes

complete the Phase 2b clinical trial
prepare for, support and advance the planned Phase 3 clinical trial of RTN-001 in uHTN
general corporate purposes
other operating expenses

Revenue and results

Revenue, Six Months Ended June 30, 2026$0
Revenue, Six Months Ended June 30, 2025$0
Revenue, Fiscal Year Ended December 31, 2025$0
Revenue, Fiscal Year Ended December 31, 2024$0
Net result, Six Months Ended June 30, 2026$7.5 million loss
Net result, Six Months Ended June 30, 2025$1.9 million loss
Net result, Fiscal Year Ended December 31, 2025$6.3 million loss
Net result, Fiscal Year Ended December 31, 2024$1.9 million loss

The risks it lists first

Limited operating history, significant losses, may never generate revenue or profit
Recurring losses raise substantial doubt about ability to continue as going concern
Require substantial additional capital, failure could force delay or termination